Say hello to CARMEN: a massively multiplexed, Cas13-based technology for nucleic acid detection, out yesterday in Nature. Its name stands for Combinatorial Arrayed Reactions for Multiplexed Evaluation of Nucleic acids, and it allows us to test many amplified samples for the presence of many viral sequences by using miniaturized detection reactions that self-organize in a microwell array. Sars-Cov2 included.Continue reading
Tag Archives: Broad Institute
CRISPR patents by numbers
According to IPStudies, over 12,000 CRISPR patent applications have been filed worldwide, falling into about 4,600 patent families. The number of issued patents is still impressive, more than 740 to date. More than half have been awarded in just two countries. Can you guess where?
China and the US, of course. Players dominating the patent landscape are the University of California and the Broad Institute – where CRISPR was respectively invented and adapted for genome editing in eukaryotes – the Chinese Academy of Sciences, the US company DuPont and the Massachusetts-based biotech firm Editas Medicine.
The struggle between UC and Broad over the standard Cas9 system is still on and is pushing the development of alternatives. CRISPR enzymes now come in approximately 50 different types, including Cpf1, C2c2, and CasY.
The partial score at the US and the EU patent offices is 34 patents granted to the Boston team and 10 to Berkeley. To learn more, read The Scientist.
CRISPR draws the first genomic map of cancer vulnerabilities
If you know the enemy and know yourself, you need not fear the result of a hundred battles. The military strategist Sun Tzu wrote it over two thousand years ago, but this quote could also apply to oncology research in the CRISPR era. Identifying the weak points of cancer cells is the first step to hit new molecular targets with the next generation of drugs.
The good news is that the Wellcome Sanger Institute has taken a giant leap toward this goal, drawing up a list of 600 candidate genes. The study just published in Nature by Mathew Garnett’s team comes with a twin paper by the Broad Institute, confirming the results by following an alternative approach. In a four-year tour de force of functional genomics, Sanger’s researchers used CRISPR to disrupt every gene in over 300 cancer models from 30 cancer types. From this amount of data, they developed a prioritization system which will guide big pharma’s hunt for new drugs.
CRISPR patent update
The patent landscape is getting more complex and fragmented, as more and more CRISPR patents are granted. The world’s eyes, however, are on the foundational patent soon to be granted to the University of California after an epic legal battle with the Broad Institute. That does not automatically mean the end of a story that will be studied in Intellectual Property textbooks. In the meantime, smaller disputes over key licenses are already heating up.
Relieving the IP burden on ag research
CRISPR is cheap and easy enough to be employed in every lab not just by major ag-biotech companies. A serious roadblock standing in the way of researchers, however, threatened to limit the technology potential for plant breeding: intellectual property (IP) rights. The good news is that two major patent holders, DuPont Pioneer and the Broad Institute of MIT and Harvard, have agreed to create a joint licensing framework for genome editing in agriculture. As a result, academic researchers are allowed to use CRISPR on plants free of charge, while biotech companies interested in commercial ag applications have a simplified procedure to access to the tools they need. Continue reading